INMB

INmune Bio Inc.

9.49
USD
2.26%
9.49
USD
2.26%
4.63 30.37
52 weeks
52 weeks

Mkt Cap 169.33M

Shares Out 17.84M

Chat
Send me real-time posts from this site at my email

INmune says FDA put on hold application to start phase 2 trial of Alzheimer's treatment

INmune Bio (NASDAQ:INMB) on Monday said the U.S. Food and Drug Administration (FDA) in May placed the company's new drug application to start its phase 2 trial of its tumor necrosis factor inhibitor XPro1595 in Alzheimer's Disease patients on hold. The FDA in its May communication also requested additional information from INMB around the chemistry manufacturing and controls of the XPro treatment. The FDA said that they will provide an official clinical hold letter to INmune in about 30 days. INMB said it plans to provide additional updates after discussions with the FDA, and added that the mid-stage trial of XPro remains open in Australia and continues to enroll patients.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue